NEW YORK, July 27, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower
RNS Number : 0885U Renalytix AI PLC 27 July 2020 Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction Renalytix AI plc Over allotment option exercise
NEW YORK, July 21, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (NASDAQ: RNLX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower
RNS Number : 6782T Renalytix AI PLC 21 July 2020 Renalytix AI plc Closing of Global Offering and resulting total voting rights Renalytix AI plc (LSE : RENX) (NASDAQ: RNLX) (" RenalytixAI " or the " Company "), an artificial intelligence -enabled in vitro diagnostics company,
RNS Number : 3256T Renalytix AI PLC 17 July 2020 This announcement contains inside information Not for release, publication or distribution, in whole or in part, in or into or from any jurisdiction where to do so would constitute a violation of the relevant laws of such jurisdiction
NEW YORK, July 16, 2020 (GLOBE NEWSWIRE) -- Renalytix AI plc (LSE: RENX) (“ RenalytixAI ” or the “ Company ”), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs,
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announces the commencement of an underwritten
Download full announcement Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, announces that all resolutions proposed at the
NEW YORK, July 13, 2020 /PRNewswire/ -- Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and lower healthcare costs, today announced the commencement of an
Download full announcement Expands access and coverage of KidneyIntelX™ into key regions for commercial growth Renalytix AI plc (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company focused on optimizing clinical management of kidney disease to drive improved patient
